Compare Gartner Inc (IT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Twist Bioscience Corp — how do they compare? Gartner Inc trades at $135.14 (market cap $9.44B), while Twist Bioscience Corp trades at $94.56 (market cap $5.45B). The key difference: Gartner Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| IT | TWST | |
|---|---|---|
Market Cap | $9.44B | $5.45B |
Sector | Technology | Health |
52-Week High | $357.98 | $102.88 |
52-Week Low | $125.68 | $24.16 |
Enterprise Value | $11.04B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $141.06, up 0.62% today, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a net income margin of 11.44% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its leadership in Gartner Magic Quadrant reports, but an ongoing legal investigation adds uncertainty. Cash flow turned negative in 2025 due to high financing outflows, though revenue remains stable around $6.5 billion.
The outlook is cautiously optimistic with a consensus price target of $157.60 suggesting 12% upside. Key opportunities include steady revenue growth and high ROE of 94.88%, but risks involve the legal probe, elevated P/B ratio of 148.08, and volatile cash flows. Investors should weigh strong fundamentals against near-term headwinds.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
